Literature DB >> 15182150

Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina.

D J Palmero1, M Ambroggi, A Brea, M De Lucas, A Fulgenzi, D Martínez, C Mosca, R Musella, M Natiello, C Gonzalez, E Abbate.   

Abstract

SETTING: An Argentinean reference hospital specialising in infectious diseases.
OBJECTIVE: To assess the outcomes of all human immunodeficiency virus (HIV) negative multidrug-resistant tuberculosis (MDR-TB) patients referred to or diagnosed at Hospital Muñiz.
DESIGN: Clinical study for the period 1996-1999, with follow-up until June 2002.
RESULTS: One hundred and forty-one adult patients (52.5% female) with resistance to two to seven drugs were studied. Fifty patients (35.5%) had not been treated previously. The most frequently used second-line drugs were 5-F-quinolones, cycloserine and ethionamide in susceptibility based individually tailored three- to five-drug regimens. Hospital admission was associated with treatment success. Forty-five episodes of severe toxicity occurred. Treatment was successful in 51.8% of cases, but follow-up of 73 patients yielded 11.9% relapse. The mortality rate was 19.1% and default was 19.9%. Logistic regression analysis was statistically significant for treatment success in relation to patient admission, residence and resistance pattern.
CONCLUSION: The burden of MDR-TB in this setting--prolonged infection, treatment cost and difficulties, low rates of cure and treatment adherence and high rates of fatality and relapse--can be improved by strengthening TB control programme activities and fighting against poverty and HIV/AIDS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182150

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  21 in total

1.  Outcome of hospitalized MDR-TB patients: Israel 2000-2005.

Authors:  D Bendayan; A Hendler; V Polansky; M Weinberger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-10-23       Impact factor: 3.267

2.  Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment.

Authors:  Molly F Franke; Sasha C Appleton; Jaime Bayona; Fernando Arteaga; Eda Palacios; Karim Llaro; Sonya S Shin; Mercedes C Becerra; Megan B Murray; Carole D Mitnick
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

3.  Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Medea Gegia; Iagor Kalandadze; Russel R Kempker; Matthew J Magee; Henry M Blumberg
Journal:  Int J Infect Dis       Date:  2012-03-17       Impact factor: 3.623

4.  Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia.

Authors:  Omar Salad Elmi; Habsah Hasan; Sarimah Abdullah; Mat Zuki Mat Jeab; Zilfalil Ba; Nyi Nyi Naing
Journal:  Malays J Med Sci       Date:  2016-06-30

Review 5.  Fluoroquinolones for the treatment of pulmonary tuberculosis.

Authors:  Susanne Moadebi; Curtis K Harder; Mark J Fitzgerald; Kevin R Elwood; Fawziah Marra
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.

Authors:  Dennis Falzon; Neel Gandhi; Giovanni B Migliori; Giovanni Sotgiu; Helen S Cox; Timothy H Holtz; Maria-Graciela Hollm-Delgado; Salmaan Keshavjee; Kathryn DeRiemer; Rosella Centis; Lia D'Ambrosio; Christoph G Lange; Melissa Bauer; Dick Menzies
Journal:  Eur Respir J       Date:  2012-10-25       Impact factor: 16.671

Review 7.  A systematic review of the effectiveness of hospital- and ambulatory-based management of multidrug-resistant tuberculosis.

Authors:  Amal Bassili; Christopher Fitzpatrick; Ejaz Qadeer; Razia Fatima; Katherine Floyd; Ernesto Jaramillo
Journal:  Am J Trop Med Hyg       Date:  2013-08       Impact factor: 2.345

8.  Patients with multidrug-resistant tuberculosis display impaired Th1 responses and enhanced regulatory T-cell levels in response to an outbreak of multidrug-resistant Mycobacterium tuberculosis M and Ra strains.

Authors:  Laura Geffner; Noemí Yokobori; Juan Basile; Pablo Schierloh; Luciana Balboa; María Mercedes Romero; Viviana Ritacco; Marisa Vescovo; Pablo González Montaner; Beatriz Lopez; Lucía Barrera; Mercedes Alemán; Eduardo Abatte; María C Sasiain; Silvia de la Barrera
Journal:  Infect Immun       Date:  2009-08-31       Impact factor: 3.441

Review 9.  Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  James C Johnston; Neal C Shahidi; Mohsen Sadatsafavi; J Mark Fitzgerald
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

10.  Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis.

Authors:  Mayara L Bastos; Hamidah Hussain; Karin Weyer; Lourdes Garcia-Garcia; Vaira Leimane; Chi Chiu Leung; Masahiro Narita; Jose M Penã; Alfredo Ponce-de-Leon; Kwonjune J Seung; Karen Shean; José Sifuentes-Osornio; Martie Van der Walt; Tjip S Van der Werf; Wing Wai Yew; Dick Menzies
Journal:  Clin Infect Dis       Date:  2014-08-05       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.